EMEA-000060-PIP09-20 - paediatric investigation plan
Canakinumab
PIPHuman
Key facts
- Invented name
- Ilaris
- Active Substance
- Canakinumab
- Therapeutic area
- Immunology-Rheumatology-Transplantation
- Decision number
- P/0075/2021
- PIP number
- EMEA-000060-PIP09-20
- Pharmaceutical form(s)
- Powder for solution for injection
- Solution for injection
- Condition(s) / indication(s)
- Treatment of Schnitzler Syndrome
- Route(s) of administration
- Subcutaneous use
- Contact for public enquiries
Novartis Europharm Limited
E-mail: paediatric.enquiries@novartis.com
Tel. +41 613241111- Decision type
- W: decision granting a waiver in all age groups for all conditions or indications
- Decision date